Literature DB >> 25059344

Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy.

Hiroyuki Karimata1, Hideaki Shimoji, Tadashi Nishimaki.   

Abstract

PURPOSE: To identify clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer following induction chemotherapy or chemoradiotherapy.
METHODS: Of 48 patients with T4 esophageal cancer who underwent induction treatment, 30 underwent R0 esophagectomy. The factors predicting R0 resection and prognostic indicators were assessed in the 48 and 30 patients, respectively, using univariate and multivariate analyses.
RESULTS: In the univariate analyses, the primary tumor response, improvement of dysphagia, the post-induction therapy Glasgow Prognostic Score, an early tumor response and the post-induction therapy serum albumin and C-reactive protein levels were significantly correlated with R0 resection. Multivariate logistic regression analyses revealed that the response status and improvement of dysphagia were independent predictors of R0 resection. The univariate analyses identified a yp-T classification (yp-T0/1 vs. yp-T2/3/4), yp-nodal status and the number of pathologically positive nodes post-therapy (≤ 1 vs. ≥ 2) as significant prognostic factors. The multivariate analysis revealed that the number of pathologically positive nodes was the only significant independent prognostic indicator.
CONCLUSION: Patients showing an early tumor response to induction treatment and improvement of dysphagia may be appropriate candidates for esophagectomy, and individualized postoperative management strategies should be developed for patients with initially unresectable T4 esophageal cancer who have ≥ 2 positive nodes post-treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059344     DOI: 10.1007/s00595-014-0980-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

1.  Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma.

Authors:  T Noguchi; H Moriyama; S Wada; S Takeno; M Wakisaka; H Mori; Y Uchida
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

2.  Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Authors:  Hubert Piessevaux; Marc Buyse; Michael Schlichting; Eric Van Cutsem; Carsten Bokemeyer; Steffen Heeger; Sabine Tejpar
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

3.  Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.

Authors:  Hideaki Shimoji; Hiroyuki Karimata; Masayoshi Nagahama; Tadashi Nishimaki
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

4.  Evaluation of the accuracy of preoperative staging in thoracic esophageal cancer.

Authors:  T Nishimaki; O Tanaka; N Ando; H Ide; H Watanabe; M Shinoda; W Takiyama; H Yamana; K Ishida; K Isono; M Endo; T Ikeuchi; T Mitomi; H Koizumi; M Imamura; T Iizuka
Journal:  Ann Thorac Surg       Date:  1999-12       Impact factor: 4.330

5.  Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Authors:  Kenneth L Meredith; Jill M Weber; Kiran K Turaga; Erin M Siegel; Jim McLoughlin; Sarah Hoffe; Melis Marcovalerio; Nilay Shah; Scott Kelley; Richard Karl
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

6.  Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer.

Authors:  Yogesh K Vashist; Julian Loos; Josephine Dedow; Michael Tachezy; Guentac Uzunoglu; Asad Kutup; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg Oncol       Date:  2010-10-28       Impact factor: 5.344

Review 7.  Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis.

Authors:  Sheraz R Markar; Alan Karthikesalingam; Marta Penna; Donald E Low
Journal:  Ann Surg Oncol       Date:  2013-11-09       Impact factor: 5.344

Review 8.  Role of salvage esophagectomy after definitive chemoradiotherapy.

Authors:  Yuji Tachimori
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-02-12

9.  Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors.

Authors:  Hideaki Shimoji; Tatsuya Kinjo; Hiroyuki Karimata; Masayoshi Nagahama; Tadashi Nishimaki
Journal:  Surg Today       Date:  2013-08-21       Impact factor: 2.549

10.  Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.

Authors:  Jessica M Leers; Shahin Ayazi; Jeffrey A Hagen; Sergei Terterov; Nancy Klipfel; Arzu Oezcelik; Emmanuele Abate; John C Lipham; Steven R DeMeester; Farzaneh Banki; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2009-04       Impact factor: 6.113

View more
  7 in total

Review 1.  Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2015-01-13       Impact factor: 2.549

Review 2.  Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.

Authors:  Peter S N van Rossum; Nadia Haj Mohammad; Frank P Vleggaar; Richard van Hillegersberg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-12-13       Impact factor: 46.802

3.  Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Norma E Farrow; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole
Journal:  Ann Thorac Surg       Date:  2019-07-26       Impact factor: 4.330

4.  Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma?

Authors:  Keijiro Sugimura; Hiroshi Miyata; Masahiko Yano; Yoshitomo Yanagimoto; Moon Jeong Ho; Shogo Kobayashi; Hidenori Takahashi; Takeshi Omori; Masayuki Ohue; Masato Sakon
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-05

5.  Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.

Authors:  Kotaro Sugawara; Koichi Yagi; Yasuhiro Okumura; Masato Nishida; Susumu Aikou; Hiroharu Yamashita; Hideomi Yamashita; Yasuyuki Seto
Journal:  Int J Clin Oncol       Date:  2019-12-11       Impact factor: 3.402

6.  Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy.

Authors:  Lin-Rui Gao; Chen Li; Weiming Han; Wenjie Ni; Wei Deng; Lijun Tan; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Wenqing Wang; Wenyang Liu; Lei Deng; Xin Wang; Tao Zhang; Jianyang Wang; Yirui Zhai; Nan Bi; Lvhua Wang; Zhouguang Hui; Ye-Xiong Li; Zefen Xiao
Journal:  Ther Adv Med Oncol       Date:  2022-07-26       Impact factor: 5.485

7.  Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.

Authors:  Hisashi Hara; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Rie Nakatsuka; Emi Harada; Takahiko Nishigaki; Yusuke Takahashi; Satoshi Nojima; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Eiichi Morii; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Br J Cancer       Date:  2016-06-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.